90 related articles for article (PubMed ID: 1370213)
1. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
Jansen B; Uckun FM; Jaszcz WB; Kersey JH
Cancer Res; 1992 Jan; 52(2):406-12. PubMed ID: 1370213
[TBL] [Abstract][Full Text] [Related]
2. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
[TBL] [Abstract][Full Text] [Related]
4. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
[TBL] [Abstract][Full Text] [Related]
5. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
8. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
[TBL] [Abstract][Full Text] [Related]
9. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
10. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
11. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
12. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel malignant B cell line with t(14;18) and t(4;11) established from a patient with acute monoblastic leukemia.
de Kroon JF; Kluin-Nelemans HC; Kluin PM; Schuuring E; van Bergen CA; Oving I; Wessels H; Willemze R; Falkenburg JH
Exp Hematol; 1997 Sep; 25(10):1062-8. PubMed ID: 9293903
[TBL] [Abstract][Full Text] [Related]
15. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
[TBL] [Abstract][Full Text] [Related]
17. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
19. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
Ek O; Reaman GH; Crankshaw DL; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Feb; 28(5-6):509-14. PubMed ID: 9613980
[TBL] [Abstract][Full Text] [Related]
20. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
